The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
| Factor | Score | Distribution | Value | Avg | Verdict |
|---|---|---|---|---|---|
Valuation | 78 | 7.2x | 20.1x | Above average | |
Growth | 70 | 68.2% | 5.6% | Above average | |
Quality | 69 | 0.8% | 7.6% | Above average | |
Safety | 41 | 295.9x | 0.4x | Near average | |
Capital Return | 41 | — | 2.19% | Near average | |
Momentum | 51 | — | — | Near average | |
Sentiment | 31 | — | — | Below average |
Theravance Biopharma, Inc. is a publicly traded stock representing ownership in the company, giving holders rights to dividends and voting.
You can buy Theravance Biopharma, Inc. shares through a licensed brokerage. Research the company's financials before investing.
Key metrics include Price-to-Earnings (P/E) ratio, Return on Equity (ROE), revenue growth, and net profit margin.
Dividend policies vary by company. Check the dividends section on the stock page for the payout history.
Risks include market volatility, sector-specific risks, regulatory changes, and company financial performance. Diversification helps reduce risk.
AI analysis from the earnings call, financials and news
This section combines price targets, revision history, analyst coverage changes, and an AI summary of what changed on the Street.
Theravance Biopharma (TBPH) stock has experienced a strong negative revision in analyst estimates, with the average price target dropping by 48% over the last 30 days to settle at $14, which is lower than the current trading price ($15.92). This decline reflects a radical shift in investment convictions, especially with Oppenheimer downgrading the stock rating from 'Outperform' to 'Perform', indicating a lower ceiling for future expectations.
Ten ratios that matter, each compared against its sector median and average — so you can see whether a number is rich or cheap relative to peers in the same sector.